Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.

BMC cancer - 15 Sept 2020

Jiang John, Adams Hans-Peter, Lange Maria, Siemann Sandra, Feldkamp Mirjam, McNamara Sylvie, Froehler Sebastian, Yaung Stephanie J, Yao Lijing, Balasubramanyam Aarthi, Tikoo Nalin, Ju Christine, Achenbach H Jost, Krügel Rainer, Palma John F

Abstract excerpt

BACKGROUND: Identifying and tracking somatic mutations in cell-free DNA (cfDNA) by next-generation sequencing (NGS) has the potential to transform the clinical management of subjects with advanced non-small cell lung cancer (NSCLC). METHODS: Baseline tumor tissue (n = 47) and longitudinal plasma (n = 445) were collected from 71 NSCLC subjects treated with chemotherapy. cfDNA was enriched using a targeted-capture...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to High-Throughput Nucleotide Sequencing

Share to Longitudinal Studies

Share to Lung Neoplasms

Share to Mutation

Share to Plasma

Source

Open in PubMed Open full text

Identifiers

PMID: 32933495
DOI: 10.1186/s12885-020-07340-z
PMCID: PMC7493404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.PMID 32933495Read ↗

Molecular profiling in lung cancerSemantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance.Semantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.Semantic proximity Read ↗

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.Semantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.Semantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinomaSemantic proximity Read ↗

Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.Semantic proximity Read ↗

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.